{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:23:07Z","timestamp":1784258587070,"version":"3.55.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Because tacrolimus has a narrow therapeutic window and exhibits both intraindividual and interindividual variability, we attempted to establish the percentage of calcineurin inhibitor (CNI) dose reduction to prevent toxicity and ensure stem cell engraftment when using this immunosuppressant with the antifungal isavuconazole (ISA). By calculating the tacrolimus concentration\/dose (C\/D) ratio, we expected to demonstrate the magnitude of change in the C\/D ratio from baseline after ISA administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We evaluated the interaction between ISA, a new triazole antifungal used in prophylaxis for invasive fungal infections, and the CNI class of immunosuppressive drugs, specifically tacrolimus, in 11 blood samples from HSCT recipients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean tacrolimus C\/D ratio increased 1.44-fold from baseline 48 h after ISA administration (P\u200a=\u200a0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although further investigation is needed, the results of this study suggest that a reduction of 18% in tacrolimus may be recommended.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad271","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:58:42Z","timestamp":1693893522000},"page":"2559-2562","source":"Crossref","is-referenced-by-count":9,"title":["Isavuconazole\u2013tacrolimus drug\u2013drug interactions in HSCT patients"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6126-8276","authenticated-orcid":false,"given":"L","family":"Fructuoso-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Hospital Pharmacy Service, Hospital Morales Meseguer , Murcia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M D","family":"Najera-Perez","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Service, Hospital Morales Meseguer , Murcia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Manresa-Ram\u00f3n","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Service, Hospital Morales Meseguer , Murcia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Torrano-Belmonte","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Service, Hospital Morales Meseguer , Murcia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Caracena-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Haematology Service, Hospital Morales Meseguer , Murcia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Pacheco-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Service, Hospital Morales Meseguer , Murcia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"2023100302100967800_dkad271-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-006-0025-x","article-title":"Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients","volume":"162","author":"Bhatti","year":"2006","journal-title":"Mycopathologia"},{"key":"2023100302100967800_dkad271-B2","first-page":"1101","article-title":"Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET)","volume":"50","author":"Khardori","year":"2010","journal-title":"Yearb Med"},{"key":"2023100302100967800_dkad271-B3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023100302100967800_dkad271-B4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.cco.0000152975.65477.7c","article-title":"The changing face of invasive fungal infections in hematopoietic cell transplant recipients","volume":"17","author":"Wingard","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"2023100302100967800_dkad271-B5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/asheducation-2018.1.228","article-title":"Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation","volume":"1","author":"Hamilton","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2023100302100967800_dkad271-B6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","article-title":"Management of drug and food interactions with azole antifungal agents in transplant recipients","volume":"30","author":"Dodds-Ashley","year":"2010","journal-title":"Pharmacotherapy"},{"key":"2023100302100967800_dkad271-B7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/0897190018790688","article-title":"Drug\u2013drug interaction between isavuconazole and tacrolimus: is empiric dose adjustment necessary?","volume":"33","author":"Kufel","year":"2020","journal-title":"J Pharm Pract"},{"key":"2023100302100967800_dkad271-B8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/1078155220940416","article-title":"Tacrolimus dose modification in patients receiving concomitant isavuconazole after hematopoietic stem cell transplantation","volume":"27","author":"Trifilio","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2023100302100967800_dkad271-B9","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/10781552211029046","article-title":"Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations","volume":"28","author":"Gu","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2023100302100967800_dkad271-B10","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.transproceed.2009.01.095","article-title":"Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients","volume":"41","author":"Yamazaki","year":"2009","journal-title":"Transplant Proc"},{"key":"2023100302100967800_dkad271-B11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1517\/17425250903044959","article-title":"Tacrolimus in hematopoietic stem cell transplantation","volume":"5","author":"Fortune","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2023100302100967800_dkad271-B12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/jcpt.12308","article-title":"Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring","volume":"40","author":"Kim","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"2023100302100967800_dkad271-B13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00970-17","article-title":"Effects of isavuconazole on the plasma concentrations of tacrolimus among solid-organ transplant patients","volume":"61","author":"Rivosecchi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302100967800_dkad271-B14","doi-asserted-by":"crossref","first-page":"e13007","DOI":"10.1111\/tid.13007","article-title":"Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: a drug-drug interaction study","volume":"21","author":"Kieu","year":"2019","journal-title":"Transpl Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/10\/2559\/51743519\/dkad271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/10\/2559\/51743519\/dkad271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:11:54Z","timestamp":1696299114000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/10\/2559\/7259932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":14,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,9,5]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad271","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,9,5]]}}}